68

Hangzhou AGS MedTech Co. Ltd. A

688581 · SHG · Healthcare / Medical Devices

50.49CNY-0.14 (-0.28%)

Price History

Full chart

Market Stats

Previous Close50.63
Open50.62
Day Range50.26 – 51.22
52-Week Range49.00 – 73.70
Volume461.12K
Market Cap4.55B
P/E (TTM)21.28
Forward P/E0.00
EPS2.65
Dividend Yield1.84%
Beta0.48
50-Day Avg53.20
200-Day Avg56.95

About

Hangzhou AGS MedTech Co., Ltd., together with its subsidiaries, engages in the research, development, production, sale, and service of endoscopic minimally invasive diagnostic and therapeutic devices in China and internationally. The company offers hemostasis products, including hemoclips and traction clips; biopsy products, such as disposable biopsy, swinging biopsy, and grasping forceps; and EMR products comprising polypectomy snares and disposable sclerotherapy needles. It also provides ESD products, which include electrosurgical generators, endoscopic C02 regulation units, endoscopic water pumps, single use electrosurgical knife combination, and bipolar coagulation forceps; ERCP products, such as disposable guide wires, disposable stone extraction baskets, stone retrieval balloons, and sphincterotome; and accessories, including disposable endoscope cleaning brushes. The company was incorporated in 2010 and is headquartered in Hangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Cheng Zhang
  • Employees779
  • HeadquartersNo. 389, Xingzhong Road, Hangzhou, China, 311199, China
  • Websitehttps://www.bioags.com

Leadership

  • Mr. Cheng ZhangChairman & GM · b. 1970
  • Mr. Yueyuan ShengDeputy General Manager · b. 1977
  • Mr. Juncan ChenCFO & Chief Accounting Officer · b. 1981
  • Mr. Qinhua ZhangBoard Secretary · b. 1980
  • Mr. Peng LiCore Technical Personnel · b. 1987
  • Mr. Chun Qi HanDeputy General Manager · b. 1983

Financials

Income Statement

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue305.47M371.11M508.75M636.63M593.74M
Growth (%)-+21.49%+37.09%+25.14%-6.74%
Cost of Revenue107.88M118.33M148.21M177.56M171.67M
Gross Profit305.47M252.79M360.54M459.08M422.07M
Gross Margin100.00%68.12%70.87%72.11%71.09%
Operating Expense093.02M133.13M170.84M198.26M
Operating Income305.47M159.76M227.41M288.24M223.81M
Operating Margin100.00%43.05%44.70%45.28%37.70%
EBITDA-171.91M258.28M352.82M275.71M
EBITDA Margin-46.32%50.77%55.42%46.44%
Net Income104.80M144.96M217.24M293.39M221.71M
Net Income Margin34.31%39.06%42.70%46.09%37.34%
R&D24.19M31.46M41.25M59.21M75.89M
R&D as % of Total Revenue7.92%8.48%8.11%9.30%12.78%
Interest Expense25.64K95.56K48.97K50.20K105.80K
Interest Expense % of Total Revenue0.01%0.03%0.01%0.01%0.02%

Balance Sheet

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets341.99M473.13M2.33B2.55B2.68B
Total Liabilities70.55M91.59M122.83M152.67M160.37M
Total Equity0381.54M2.21B2.40B2.52B
Cash204.53M213.38M1.95B1.03B1.18B

Cash Flow

Currency: CNY2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow118.25M156.38M221.45M315.80M151.20M
Capital Expenditure15.66M60.12M51.57M49.60M63.47M
Free Cash Flow118.25M96.26M169.88M266.19M87.74M
Dividends Paid49.05M35.95M43.98M83.33M111.20M
FCF to OCF100.00%61.56%76.71%84.29%58.03%
Dividend Paid to FCF41.48%37.35%25.89%31.30%126.73%

Key Statistics & Ratios

Market Cap4.55B
Enterprise Value2.64B
Trailing P/E21.28
Forward P/E0.00
Price / Sales7.68
Price / Book1.78
EPS2.65
Book Value31.42
Revenue (TTM)592.88M
Gross Profit (TTM)421.02M
EBITDA213.84M
Profit Margin36.06%
Operating Margin36.22%
Return on Equity8.57%
Return on Assets4.70%
Shares Outstanding80.74M
Shares Float34.88M
Beta0.48
Dividend Yield1.84%
Dividend Rate1.04
Payout Ratio91.04%

Dividends

20261×
1.04Jun 17, 2026
20251×
1.37Jul 9, 2025
20241×
1.45Jun 21, 2024
20231×
0.54Jul 20, 2023

Stock Splits

  • Jun 21, 20241.4:1